Lasa Supergenerics Ltd.

As of June 30, 2026, Lasa Supergenerics Ltd. carries a market capitalization of 378.77M, placing it among publicly traded companies globally. Its enterprise value stands at 378.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Lasa Supergenerics Ltd. has 50.10M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 378.77M versus a market cap of 378.77M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.69M in revenue per employee across its workforce of 37.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Lasa Supergenerics Ltd. recorded 10.08M in income tax expense. The company reported a pretax loss of -155.42M and -165.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 19, 2026, Lasa Supergenerics Ltd.'s stock has declined approximately 52.97% over the past 52 weeks. The 50-day moving average sits at 6.94, while the 200-day moving average is 8.00.

Over the twelve months ended June 30, 2026, Lasa Supergenerics Ltd. generated 63.56M in revenue and converted that into -165.50M in net income, yielding earnings per share of -3.30. EBITDA reached -91.96M, while operating income came in at -142.68M.

Over the twelve months ended June 30, 2026, Lasa Supergenerics Ltd. posted a gross margin of -57.16, reflecting its pricing power and cost economics. The operating margin of -224.50 and net profit margin of -260.40 provide insight into operational efficiency.